These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7949255)

  • 1. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.
    Kiu MC; Liaw CC; Yang TS; Lai GM; Hsi SN; Lu CS
    Anticancer Drugs; 1994 Aug; 5(4):480-2. PubMed ID: 7949255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient neurologic disturbances induced by high-dose methotrexate treatment.
    Jaffe N; Takaue Y; Anzai T; Robertson R
    Cancer; 1985 Sep; 56(6):1356-60. PubMed ID: 3875390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose systemic methotrexate-associated acute neurologic dysfunction.
    Packer RJ; Grossman RI; Belasco JB
    Med Pediatr Oncol; 1983; 11(3):159-61. PubMed ID: 6602269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
    Pongracz N; Kelaridis T; Ritschl P
    Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neo-adjuvant therapy in childhood osteogenic sarcoma: a pilot study of selective postoperative chemotherapy based on response to preoperative high-dose methotrexate].
    Sasaki K; Matsuoka H; Murakami T; Fujimoto T; Takayanagi F; Sawai K; Niwa J; Hara K
    Gan To Kagaku Ryoho; 1986 May; 13(5):1837-45. PubMed ID: 3486634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose methotrexate/leucovorin adjuvant chemotherapy of osteogenic sarcoma: biochemical effects in DNA-synthesis of bone marrow cells (author's transl)].
    Sauer H; Wilmanns W
    Blut; 1978 Jun; 36(6):357-61. PubMed ID: 306851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Spectral EEG analysis in children treated with high-dose methotrexate].
    Fujii Y; Hongo T; Horikoshi Y; Mizuno Y; Ichimura M; Sugie Y; Sugie H; Igarashi Y
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):659-67. PubMed ID: 3493731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.
    Jaffe N; Paed D; Farber S; Traggis D; Geiser C; Kim BS; Das L; Frauenberger G; Djerassi I; Cassady JR
    Cancer; 1973 Jun; 31(6):1367-73. PubMed ID: 4541163
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient encephalopathy during the late course of treatment with high-dose methotrexate.
    Fritsch G; Urban C
    Cancer; 1984 May; 53(9):1849-51. PubMed ID: 6584197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
    Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
    Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
    [No Abstract]   [Full Text] [Related]  

  • 13. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
    Allen JC; Rosen G
    Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
    Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
    Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.
    Goorin A; Strother D; Poplack D; Letvak LA; George M; Link M
    Med Pediatr Oncol; 1995 Jun; 24(6):362-7. PubMed ID: 7715542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful desensitization to high-dose methotrexate after systemic anaphylaxis.
    Davis KA; Williams P; Walker JC
    Ann Allergy Asthma Immunol; 2003 Jan; 90(1):87-9. PubMed ID: 12546343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EEG-slowing after high-dose Methotrexate with citrovorumfactor-rescue. A spectralanalytic study (author's transl)].
    Korinthenberg R; Lütkenhöner B; Palm D; Ritter J
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1982 Mar; 13(1):22-7. PubMed ID: 6806066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
    Yamada K; Takahashi M; Yoshida M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma.
    Rosen G; Tan C; Sanmaneechai A; Beattie EJ; Marcove R; Murphy ML
    Cancer; 1975 Mar; 35(3 suppl):936-45. PubMed ID: 1078642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma.
    Jaffe N; Traggis D; Cassady JR; Filler RM; Watts H; Frei E
    Int J Radiat Oncol Biol Phys; 1977; 2(3-4):261-6. PubMed ID: 301137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.